MeSH term
Frequency | Condition_Probility | Humans | 608 | 0.0 |
Antibodies, Monoclonal/chemistry | 2 | 2.0 |
Immunohistochemistry | 13 | 0.0 |
Time Factors | 27 | 0.0 |
Animals | 233 | 0.0 |
Ascorbic Acid/pharmacology | 3 | 5.0 |
Cells, Cultured | 15 | 0.0 |
Cholinesterase Inhibitors/pharmacology | 18 | 42.0 |
Mice | 75 | 0.0 |
Rats | 74 | 0.0 |
Research Support, Non-U.S. Gov't | 301 | 0.0 |
Acetylcholinesterase/*metabolism | 136 | 85.0 |
Adult | 106 | 0.0 |
Brain/*enzymology/*radionuclide imaging | 2 | 100.0 |
Carbon Radioisotopes | 3 | 3.0 |
Dose-Response Relationship, Radiation | 2 | 0.0 |
Indans/pharmacology | 4 | 66.0 |
Kinetics | 81 | 0.0 |
Male | 210 | 0.0 |
Tissue Distribution | 12 | 0.0 |
*Tomography, Emission-Computed | 3 | 6.0 |
Acetylcholine/*metabolism | 4 | 12.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
Biological Markers | 6 | 0.0 |
Hela Cells | 2 | 0.0 |
Microscopy, Electron | 14 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 100 | 0.0 |
Acetylcholinesterase/blood/*drug effects | 2 | 100.0 |
Middle Aged | 119 | 0.0 |
Occupational Exposure/*adverse effects | 4 | 4.0 |
Organophosphorus Compounds/*adverse effects | 3 | 60.0 |
Pesticides/*adverse effects | 3 | 23.0 |
Retrospective Studies | 5 | 0.0 |
Aged | 113 | 0.0 |
Aged, 80 and over | 45 | 0.0 |
Alzheimer Disease/*drug therapy | 11 | 78.0 |
Cholinesterase Inhibitors/adverse effects/*therapeutic use | 3 | 75.0 |
Female | 206 | 0.0 |
*Phenylcarbamates | 10 | 66.0 |
Prospective Studies | 4 | 0.0 |
Severity of Illness Index | 5 | 0.0 |
Treatment Outcome | 7 | 0.0 |
Acetylcholinesterase/*analysis | 41 | 74.0 |
Adolescent | 43 | 0.0 |
Child | 37 | 0.0 |
Histocytochemistry | 36 | 5.0 |
Nerve Fibers/*enzymology | 3 | 60.0 |
Neurons/*enzymology | 5 | 7.0 |
Algorithms | 4 | 1.0 |
Binding, Competitive | 7 | 0.0 |
Cholinesterase Inhibitors/chemistry/*pharmacology | 2 | 100.0 |
Electrophorus | 7 | 87.0 |
Ligands | 7 | 0.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Models, Molecular | 19 | 0.0 |
Spectrum Analysis, Mass | 4 | 0.0 |
Structure-Activity Relationship | 24 | 0.0 |
Brain/enzymology | 15 | 8.0 |
Butyrylcholinesterase/metabolism | 12 | 85.0 |
Cholinesterase Inhibitors/*chemical synthesis/chemistry/pharmacology | 4 | 100.0 |
In Vitro | 46 | 0.0 |
Acetylcholinesterase/metabolism | 45 | 58.0 |
Case-Control Studies | 5 | 0.0 |
Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Glycosylation | 3 | 0.0 |
Biopsy | 13 | 0.0 |
Child, Preschool | 30 | 0.0 |
Infant | 27 | 0.0 |
Brain/*drug effects/metabolism | 2 | 11.0 |
Cattle | 27 | 0.0 |
Cholinesterase Inhibitors/chemistry/pharmacology | 2 | 100.0 |
Dose-Response Relationship, Drug | 37 | 0.0 |
Piperidines/pharmacology | 3 | 5.0 |
Rats, Wistar | 16 | 1.0 |
Salivation/drug effects | 2 | 50.0 |
Tacrine/pharmacology | 5 | 100.0 |
Temperature | 5 | 0.0 |
Butyrylcholinesterase/*metabolism | 13 | 68.0 |
Cholinesterase Inhibitors/*therapeutic use | 10 | 62.0 |
Alzheimer Disease/*drug therapy/enzymology | 2 | 100.0 |
Comparative Study | 96 | 0.0 |
Acetylcholinesterase/*chemistry | 5 | 83.0 |
Binding Sites | 24 | 0.0 |
Cholinesterase Inhibitors/*chemistry/pharmacology | 2 | 66.0 |
Computer Simulation | 5 | 1.0 |
Crystallization | 2 | 0.0 |
Crystallography, X-Ray | 4 | 0.0 |
Protein Conformation | 16 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 76 | 0.0 |
Species Specificity | 21 | 0.0 |
Double-Blind Method | 11 | 0.0 |
Models, Biological | 6 | 0.0 |
Rats, Inbred F344 | 4 | 1.0 |
Biological Transport | 3 | 0.0 |
Hippocampus/*metabolism | 2 | 2.0 |
Mice, Inbred Strains | 6 | 0.0 |
Cholinergic Fibers/enzymology/*pathology | 4 | 80.0 |
English Abstract | 45 | 0.0 |
Neurons/*cytology/enzymology | 2 | 18.0 |
Disease Models, Animal | 12 | 0.0 |
Acetylcholinesterase/immunology/isolation & purification/*metabolism | 2 | 100.0 |
Antibodies | 3 | 0.0 |
Brain/metabolism | 2 | 0.0 |
Chromatography, Affinity | 7 | 0.0 |
Enteric Nervous System/*pathology | 2 | 50.0 |
Hirschsprung Disease/*diagnosis | 4 | 100.0 |
Cholinesterase Inhibitors/*chemical synthesis/chemistry | 4 | 80.0 |
Molecular Conformation | 7 | 3.0 |
Physostigmine/*analogs & derivatives/*chemical synthesis/chemistry | 2 | 100.0 |
Acetates/*diagnostic use | 2 | 100.0 |
Alzheimer Disease/metabolism/*radionuclide imaging | 2 | 100.0 |
Blood Specimen Collection | 2 | 4.0 |
Carbon Radioisotopes/diagnostic use | 5 | 8.0 |
Least-Squares Analysis | 2 | 5.0 |
Piperidines/*diagnostic use | 2 | 40.0 |
Tomography, Emission-Computed/*methods | 7 | 30.0 |
Brain/drug effects/enzymology | 5 | 41.0 |
Carboxylic Ester Hydrolases/*antagonists & inhibitors | 2 | 100.0 |
Chickens | 7 | 0.0 |
Cholinesterase Inhibitors/*toxicity | 12 | 85.0 |
Half-Life | 5 | 0.0 |
Insecticides/*toxicity | 7 | 35.0 |
Neuroblastoma/enzymology | 3 | 42.0 |
*Organophosphorus Compounds | 14 | 46.0 |
Quantitative Structure-Activity Relationship | 2 | 6.0 |
Regression Analysis | 4 | 0.0 |
Tumor Cells, Cultured | 9 | 0.0 |
Alzheimer Disease/*drug therapy/physiopathology | 2 | 50.0 |
Clinical Trials | 4 | 0.0 |
Neuropsychological Tests | 7 | 2.0 |
Receptors, Nicotinic/*drug effects/physiology | 2 | 66.0 |
Acetylcholinesterase/chemistry/*genetics/metabolism | 2 | 100.0 |
Amino Acid Sequence | 21 | 0.0 |
*Gene Expression Regulation, Enzymologic | 6 | 1.0 |
Molecular Sequence Data | 22 | 0.0 |
RNA, Messenger/genetics/metabolism | 5 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Acetylcholinesterase/biosynthesis | 3 | 75.0 |
Cell Division | 3 | 0.0 |
Cell Line | 20 | 0.0 |
DNA/metabolism | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Ploidies | 2 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Acute Disease | 5 | 0.0 |
*Agriculture | 2 | 20.0 |
Insecticides/*adverse effects | 2 | 22.0 |
*Occupational Exposure | 3 | 2.0 |
Protective Clothing | 2 | 50.0 |
Risk Factors | 4 | 0.0 |
Drug Design | 3 | 0.0 |
Molecular Weight | 9 | 0.0 |
Neuroblastoma | 4 | 2.0 |
Organophosphorus Compounds/*pharmacology | 8 | 36.0 |
Predictive Value of Tests | 5 | 0.0 |
Reproducibility of Results | 10 | 0.0 |
Statistics | 5 | 1.0 |
Thermodynamics | 5 | 1.0 |
Acetylcholinesterase/genetics/*metabolism | 3 | 60.0 |
Chromosome Mapping | 8 | 0.0 |
Oxidation-Reduction | 4 | 0.0 |
Thiobarbituric Acid Reactive Substances/metabolism | 2 | 4.0 |
Acetylcholine/metabolism | 8 | 26.0 |
Cholinesterase Inhibitors/*pharmacology/therapeutic use | 5 | 100.0 |
Cognition/drug effects | 2 | 13.0 |
Frontal Lobe/metabolism | 2 | 6.0 |
Haplorhini | 4 | 1.0 |
Indans/*pharmacology/therapeutic use | 2 | 100.0 |
Memory/drug effects | 5 | 33.0 |
Piperidines/*pharmacology/therapeutic use | 2 | 40.0 |
Chromatography, High Pressure Liquid | 6 | 0.0 |
Hydrolysis | 16 | 2.0 |
Molecular Structure | 6 | 0.0 |
Acetylcholinesterase/*drug effects/metabolism | 4 | 100.0 |
Erythrocyte Membrane/*drug effects/enzymology | 4 | 80.0 |
Acetylcholinesterase/*diagnostic use | 2 | 100.0 |
Biopsy, Needle | 3 | 0.0 |
Indicators and Reagents | 4 | 1.0 |
Infant, Newborn | 28 | 0.0 |
Intestinal Mucosa/*pathology | 2 | 8.0 |
Rectum/pathology | 2 | 11.0 |
Sensitivity and Specificity | 8 | 0.0 |
Chemical Warfare Agents/toxicity | 3 | 100.0 |
Chick Embryo | 3 | 0.0 |
Pregnancy | 32 | 0.0 |
Transfection | 13 | 0.0 |
Acetates/diagnostic use/pharmacokinetics | 2 | 100.0 |
Piperidines/diagnostic use/pharmacokinetics | 2 | 100.0 |
Reference Values | 17 | 0.0 |
Tomography, Emission-Computed | 11 | 10.0 |
Injections, Intravenous | 4 | 0.0 |
Leukocyte Count | 3 | 0.0 |
Acetylcholinesterase/chemistry/*metabolism | 7 | 87.0 |
Torpedo | 10 | 26.0 |
*Gene Expression Regulation | 2 | 0.0 |
Receptors, Muscarinic/*metabolism | 3 | 8.0 |
Acetylcholinesterase/chemistry | 3 | 42.0 |
Alzheimer Disease/drug therapy | 6 | 40.0 |
*Drug Design | 4 | 4.0 |
Acetylcholinesterase/blood/*metabolism | 6 | 85.0 |
Chromatography | 2 | 1.0 |
PC12 Cells | 3 | 0.0 |
Alzheimer Disease/*metabolism | 5 | 2.0 |
Choline O-Acetyltransferase/metabolism | 14 | 9.0 |
Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Mitochondria/enzymology | 2 | 1.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Drug Interactions | 8 | 0.0 |
Neuroprotective Agents/*therapeutic use | 2 | 8.0 |
Brain/*drug effects/enzymology | 4 | 50.0 |
Cholinesterase Inhibitors/pharmacology/*therapeutic use | 2 | 66.0 |
Nerve Fibers/pathology | 2 | 8.0 |
Nerve Tissue Proteins/analysis | 2 | 2.0 |
Acetylcholinesterase/*genetics | 18 | 94.0 |
Cyclic AMP/*metabolism | 2 | 0.0 |
Gene Expression Regulation, Enzymologic/*physiology | 2 | 2.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Monte Carlo Method | 2 | 2.0 |
Electrophoresis, Polyacrylamide Gel | 20 | 0.0 |
Allosteric Regulation | 3 | 4.0 |
Cholinesterase Inhibitors/*pharmacology | 47 | 72.0 |
Acetylcholinesterase/*analysis/immunology | 2 | 100.0 |
Rabbits | 17 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Acetylcholinesterase/*cerebrospinal fluid | 24 | 92.0 |
Catalase/metabolism | 3 | 4.0 |
*Oxidative Stress | 2 | 0.0 |
Sulfhydryl Compounds/metabolism | 2 | 5.0 |
Acetylthiocholine/metabolism | 10 | 83.0 |
Paraoxon/*pharmacology | 3 | 75.0 |
Brain/*enzymology/radionuclide imaging | 3 | 60.0 |
Acetylcholinesterase/*blood | 49 | 92.0 |
Erythrocytes/*enzymology | 42 | 8.0 |
Organophosphorus Compounds/blood/*poisoning | 2 | 100.0 |
Mice, Inbred BALB C | 9 | 0.0 |
Phenothiazines/pharmacology | 3 | 42.0 |
Culture Techniques | 2 | 0.0 |
Hirschsprung Disease/*enzymology/*pathology | 2 | 100.0 |
Stereoisomerism | 8 | 2.0 |
Electroencephalography | 2 | 0.0 |
Cholinesterase Inhibitors/*metabolism/pharmacology | 2 | 66.0 |
Hydrogen-Ion Concentration | 7 | 0.0 |
Macromolecular Substances | 11 | 0.0 |
Substrate Specificity | 13 | 0.0 |
Respiration/drug effects | 2 | 25.0 |
Receptors, Nicotinic/*drug effects | 2 | 50.0 |
Synaptic Transmission/drug effects | 3 | 11.0 |
Blotting, Western | 13 | 0.0 |
Cloning, Molecular | 7 | 0.0 |
Acetylcholinesterase/*chemistry/*metabolism | 2 | 100.0 |
Models, Chemical | 4 | 1.0 |
Cholinesterase Inhibitors/administration & dosage/*pharmacology | 2 | 100.0 |
Pregnancy/*metabolism | 2 | 3.0 |
Cholinergic Fibers/enzymology/*ultrastructure | 2 | 66.0 |
Mice, Knockout | 2 | 0.0 |
Motor Endplate/*enzymology | 3 | 60.0 |
Organ Specificity | 8 | 0.0 |
Acetylcholinesterase/genetics | 2 | 50.0 |
Cognition Disorders/diagnosis | 2 | 15.0 |
Chromosomes, Human, Pair 7 | 2 | 1.0 |
*Transcription, Genetic | 2 | 0.0 |
Butyrylcholinesterase/*blood | 8 | 50.0 |
Environmental Monitoring/*methods | 3 | 13.0 |
Enzyme Stability | 3 | 1.0 |
Erythrocytes/drug effects/*enzymology | 5 | 25.0 |
Freezing | 3 | 3.0 |
Occupational Exposure/*analysis | 2 | 7.0 |
Acetylcholinesterase/drug effects/*metabolism | 4 | 100.0 |
Pedigree | 3 | 0.0 |
Phenotype | 5 | 0.0 |
Brain/*enzymology | 33 | 17.0 |
Enzyme-Linked Immunosorbent Assay/methods | 3 | 1.0 |
Peptide Library | 2 | 1.0 |
Superoxide Dismutase/metabolism | 3 | 3.0 |
Acetylcholinesterase/analysis | 16 | 45.0 |
Chronic Disease | 4 | 0.0 |
Diagnosis, Differential | 10 | 0.0 |
Rectum/enzymology/pathology | 4 | 100.0 |
Staining and Labeling | 8 | 1.0 |
Butyrylcholinesterase/blood | 3 | 50.0 |
Cholinesterase Inhibitors/administration & dosage/*therapeutic use | 2 | 66.0 |
Drug Administration Schedule | 7 | 0.0 |
Trichlorfon/administration & dosage/*therapeutic use | 2 | 100.0 |
Acetylcholinesterase/*deficiency/*genetics | 2 | 66.0 |
COS Cells | 3 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Gene Expression | 4 | 0.0 |
*Muscle Proteins | 2 | 0.0 |
Phosphorylation | 11 | 0.0 |
Propidium/pharmacology | 3 | 21.0 |
Acetylcholinesterase/*blood/genetics | 3 | 100.0 |
Aryldialkylphosphatase | 2 | 1.0 |
Erythrocytes/enzymology | 31 | 7.0 |
Cholinesterase Inhibitors/metabolism/*pharmacology | 2 | 66.0 |
Acetylcholinesterase/blood | 20 | 74.0 |
Apolipoproteins E/genetics | 2 | 0.0 |
DNA/analysis | 2 | 0.0 |
Gene Dosage | 2 | 0.0 |
Cholinesterase Inhibitors/poisoning | 3 | 100.0 |
Spectrophotometry, Ultraviolet | 3 | 1.0 |
Catalysis | 5 | 0.0 |
Mice, Transgenic | 6 | 0.0 |
Enzyme Tests | 5 | 7.0 |
Hirschsprung Disease/enzymology/*pathology | 2 | 100.0 |
Intestinal Mucosa/enzymology/innervation | 2 | 100.0 |
Cholinesterases/*analysis | 8 | 80.0 |
Organophosphorus Compounds | 3 | 25.0 |
Acetylcholinesterase/isolation & purification/*metabolism | 2 | 100.0 |
Drugs, Chinese Herbal/*therapeutic use | 2 | 2.0 |
Malondialdehyde/blood | 2 | 3.0 |
*Phytotherapy | 6 | 6.0 |
Superoxide Dismutase/blood | 2 | 4.0 |
Muscles/innervation | 3 | 18.0 |
Neuromuscular Junction/*enzymology | 3 | 50.0 |
Propidium/metabolism/pharmacology | 2 | 100.0 |
Acetylcholinesterase/*immunology | 10 | 83.0 |
Rats, Sprague-Dawley | 7 | 0.0 |
Acetylcholinesterase/immunology/*metabolism | 2 | 100.0 |
Enzyme-Linked Immunosorbent Assay | 10 | 0.0 |
Immunoblotting | 9 | 0.0 |
Setaria Nematode/*enzymology/immunology | 2 | 100.0 |
Cholinesterase Inhibitors/*adverse effects | 5 | 100.0 |
Biological Markers/analysis | 2 | 0.0 |
Cholinergic Fibers/*physiology | 2 | 25.0 |
Drug Synergism | 3 | 0.0 |
Indoles/*pharmacology | 2 | 2.0 |
Membrane Fluidity/drug effects | 2 | 10.0 |
Acetylcholinesterase/*chemistry/genetics/metabolism | 2 | 100.0 |
Cell Membrane/enzymology | 6 | 2.0 |
Mutation | 6 | 0.0 |
Butyrylcholinesterase/*cerebrospinal fluid | 5 | 71.0 |
*Cholinesterase Inhibitors | 7 | 70.0 |
Risk Assessment | 4 | 0.0 |
Acetylcholinesterase/drug effects/metabolism | 2 | 66.0 |
*Carbamates | 3 | 37.0 |
Cholinesterases/blood | 6 | 27.0 |
Diet | 2 | 0.0 |
Food Contamination | 2 | 6.0 |
Acetylcholinesterase/blood/drug effects | 2 | 100.0 |
Cholinesterase Reactivators/pharmacology | 5 | 71.0 |
Insecticides/pharmacology | 2 | 50.0 |
Obidoxime Chloride/pharmacology | 5 | 100.0 |
Oximes/pharmacology | 3 | 60.0 |
Pralidoxime Compounds/pharmacology | 6 | 85.0 |
Pyridines/pharmacology | 3 | 1.0 |
Pyridinium Compounds/pharmacology | 4 | 50.0 |
Radioactive Tracers | 2 | 33.0 |
Animals, Newborn | 2 | 0.0 |
Myocardium/enzymology | 2 | 2.0 |
Aging/*metabolism | 5 | 2.0 |
Analysis of Variance | 4 | 0.0 |
Biotransformation | 2 | 0.0 |
Paraoxon/toxicity | 2 | 66.0 |
Chromatography, Thin Layer | 2 | 1.0 |
Cholinesterase Inhibitors/therapeutic use | 2 | 18.0 |
Electrocardiography/drug effects | 2 | 6.0 |
Heart/*innervation | 4 | 23.0 |
Insecticides/*pharmacology | 3 | 27.0 |
Neurons/*drug effects | 2 | 5.0 |
Autoradiography | 3 | 0.0 |
Brain/*metabolism | 3 | 0.0 |
Guinea Pigs | 7 | 0.0 |
Cell Differentiation | 4 | 0.0 |
Exons | 4 | 0.0 |
Oligonucleotides, Antisense | 2 | 2.0 |
RNA, Messenger | 2 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
Up-Regulation | 3 | 0.0 |
Administration, Oral | 4 | 0.0 |
Cholinesterase Inhibitors/adverse effects/*pharmacokinetics/pharmacology | 2 | 100.0 |
Indans/adverse effects/*pharmacokinetics/pharmacology | 2 | 100.0 |
Piperidines/adverse effects/*pharmacokinetics/pharmacology | 2 | 100.0 |
Age Factors | 8 | 0.0 |
Environmental Exposure | 4 | 2.0 |
Sex Factors | 2 | 0.0 |
Erythrocyte Membrane/*enzymology | 13 | 40.0 |
Muscles/enzymology | 3 | 5.0 |
Receptors, Muscarinic/*physiology | 2 | 9.0 |
*Variation (Genetics) | 2 | 0.0 |
Xenopus | 2 | 0.0 |
Acetylcholinesterase/analysis/*metabolism | 2 | 66.0 |
Dogs | 2 | 0.0 |
Electrophysiology | 3 | 0.0 |
Neurons/drug effects/*enzymology | 2 | 22.0 |
Neurons/enzymology | 5 | 11.0 |
Physostigmine/*analogs & derivatives/pharmacology | 2 | 50.0 |
Lethal Dose 50 | 9 | 15.0 |
Adenosinetriphosphatase/*metabolism | 3 | 7.0 |
Cerebral Cortex/*drug effects/*enzymology | 2 | 100.0 |
Enzyme Activation | 8 | 0.0 |
Behavior, Animal/*drug effects | 2 | 9.0 |
Enzyme Activation/drug effects | 5 | 0.0 |
Hydrolysis/drug effects | 2 | 8.0 |
Brain Mapping | 2 | 1.0 |
Butyrylcholinesterase/*analysis | 6 | 100.0 |
Acetylcholinesterase/cerebrospinal fluid | 4 | 100.0 |
Alzheimer Disease/*cerebrospinal fluid/enzymology | 3 | 100.0 |
Biological Markers/cerebrospinal fluid | 3 | 11.0 |
Cholinesterases/*cerebrospinal fluid | 6 | 85.0 |
Acetylcholinesterase/*blood/metabolism | 3 | 75.0 |
Acetylcholinesterase/*immunology/isolation & purification | 2 | 100.0 |
Cross Reactions | 5 | 0.0 |
Microfilaria/enzymology | 2 | 100.0 |
Wuchereria bancrofti/*enzymology/immunology | 2 | 100.0 |
Aging/metabolism | 2 | 1.0 |
Choline O-Acetyltransferase/*metabolism | 4 | 3.0 |
Genotype | 4 | 0.0 |
Follow-Up Studies | 4 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 4 | 0.0 |
Inhibitory Concentration 50 | 4 | 1.0 |
Plant Extracts/administration & dosage/*pharmacology/therapeutic use | 4 | 40.0 |
Amniotic Fluid/*chemistry/metabolism | 2 | 50.0 |
False Positive Reactions | 4 | 1.0 |
Prenatal Diagnosis/*methods | 4 | 3.0 |
India | 2 | 0.0 |
Drug Combinations | 4 | 0.0 |
Longitudinal Studies | 3 | 0.0 |
Thymectomy | 2 | 6.0 |
Insecticides/*poisoning | 5 | 50.0 |
Parathion/*poisoning | 4 | 100.0 |
Poisoning/*drug therapy | 2 | 100.0 |
Erythrocyte Membrane/enzymology | 6 | 37.0 |
Electromyography | 3 | 1.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Motor Neurons/*pathology | 2 | 10.0 |
Neuromuscular Junction/*pathology | 2 | 100.0 |
Biological Markers/blood | 4 | 0.0 |
Alleles | 4 | 0.0 |
Pregnancy Trimester, First | 3 | 1.0 |
Acetylcholinesterase/*biosynthesis | 3 | 100.0 |
Bone Marrow Cells | 2 | 0.0 |
Cell Differentiation/drug effects | 5 | 0.0 |
Enzyme Induction | 2 | 0.0 |
Megakaryocytes/*enzymology | 3 | 37.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Occupational Exposure/adverse effects | 2 | 9.0 |
*Organothiophosphorus Compounds | 2 | 100.0 |
RNA, Messenger/*metabolism | 3 | 0.0 |
Carboxylic Ester Hydrolases/*antagonists & inhibitors/metabolism | 2 | 100.0 |
Alzheimer Disease/*enzymology/pathology | 9 | 31.0 |
Brain/pathology | 2 | 0.0 |
Erythrocytes/drug effects/enzymology | 8 | 27.0 |
Subcellular Fractions/enzymology | 2 | 2.0 |
Lectins/metabolism | 2 | 2.0 |
*Acetylcholinesterase | 2 | 100.0 |
Cisplatin/*pharmacology | 2 | 1.0 |
Colony-Forming Units Assay | 3 | 0.0 |
Hematopoiesis/*drug effects | 2 | 2.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Environmental Exposure/*adverse effects | 2 | 7.0 |
Prevalence | 2 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Receptors, Muscarinic/*analysis | 2 | 18.0 |
Phenylalanine | 2 | 7.0 |
Point Mutation | 3 | 0.0 |
Tryptophan | 2 | 7.0 |
Tyrosine | 2 | 1.0 |
Magnetic Resonance Imaging | 3 | 0.0 |
Acetylcholinesterase/*drug effects | 3 | 100.0 |
Enzyme Inhibitors | 2 | 2.0 |
Butyrylcholinesterase/*genetics | 3 | 11.0 |
Cholinesterases/genetics | 2 | 100.0 |
Acetylcholinesterase/*blood/isolation & purification | 2 | 100.0 |
Detergents | 6 | 5.0 |
Octoxynol | 7 | 12.0 |
Avoidance Learning/drug effects | 3 | 37.0 |
Cholinesterase Inhibitors/toxicity | 4 | 66.0 |
Trimedoxime/pharmacology | 2 | 100.0 |
*Chromosomes, Human, Pair 7 | 3 | 1.0 |
Myelodysplastic Syndromes/*genetics | 2 | 2.0 |
Alzheimer Disease/*enzymology | 10 | 21.0 |
Fluorescent Dyes | 2 | 0.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Thiazoles/metabolism | 2 | 9.0 |
Base Sequence | 10 | 0.0 |
DNA Primers | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Drug Monitoring | 2 | 4.0 |
Buffers | 2 | 1.0 |
Cell Count | 3 | 0.0 |
Cerebral Cortex/*enzymology | 2 | 18.0 |
Butyrylcholinesterase/genetics | 3 | 42.0 |
Choline O-Acetyltransferase/analysis | 6 | 12.0 |
Tyrosine 3-Monooxygenase/analysis | 4 | 4.0 |
Synaptic Transmission | 4 | 10.0 |
Insecticides/toxicity | 2 | 66.0 |
Radioligand Assay | 3 | 0.0 |
Receptors, Cholinergic/drug effects | 2 | 40.0 |
Soman/poisoning | 2 | 100.0 |
Cholinesterase Reactivators/*pharmacology | 11 | 100.0 |
Erythrocytes/*drug effects/enzymology | 3 | 27.0 |
Pyridines/*pharmacology | 2 | 3.0 |
Pyridinium Compounds/*pharmacology | 8 | 88.0 |
Cats | 5 | 1.0 |
Cholinesterases/*metabolism | 10 | 71.0 |
Gestational Age | 10 | 1.0 |
Immunoenzyme Techniques | 9 | 0.0 |
Centrifugation, Density Gradient | 12 | 3.0 |
Hirschsprung Disease/*enzymology | 2 | 100.0 |
Protein Binding | 4 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Neuropeptide Y/analysis | 3 | 4.0 |
Thiolester Hydrolases/analysis | 3 | 8.0 |
Ubiquitin Thiolesterase | 3 | 2.0 |
DNA Primers/genetics | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Butyrylthiocholine/metabolism | 3 | 42.0 |
Carbamates/pharmacology | 2 | 18.0 |
Pyridostigmine Bromide/*pharmacology | 4 | 19.0 |
Acylation | 3 | 4.0 |
Acetylcholinesterase/*analysis/blood | 4 | 100.0 |
Amniotic Fluid/enzymology | 2 | 22.0 |
Chromatography, Gel | 2 | 0.0 |
Mathematics | 3 | 1.0 |
Time | 2 | 6.0 |
Phosphatidylinositol Diacylglycerol-Lyase | 5 | 5.0 |
Fluorescence | 2 | 0.0 |
Abdominal Muscles/abnormalities | 3 | 60.0 |
Amniocentesis | 7 | 7.0 |
Immunoelectrophoresis | 3 | 1.0 |
Neural Tube Defects/diagnosis | 3 | 16.0 |
Pregnancy Trimester, Second | 4 | 1.0 |
Prenatal Diagnosis | 5 | 2.0 |
Alternative Splicing | 2 | 0.0 |
Antibodies, Helminth/immunology | 2 | 15.0 |
Brain Chemistry/*drug effects | 2 | 12.0 |
Dopamine/metabolism | 2 | 1.0 |
Serotonin/metabolism | 4 | 5.0 |
Antibody Specificity | 7 | 0.0 |
Solubility | 6 | 0.0 |
Carboxylic Ester Hydrolases/*drug effects | 2 | 100.0 |
Erythrocyte Membrane/drug effects/enzymology | 4 | 100.0 |
Erythrocyte Membrane/drug effects/*enzymology | 2 | 50.0 |
Reference Standards | 3 | 1.0 |
Soman/*pharmacology | 3 | 100.0 |
Butyrylcholinesterase/immunology | 3 | 100.0 |
Restriction Mapping | 4 | 0.0 |
Amniotic Fluid/*enzymology | 12 | 52.0 |
Anencephaly/enzymology | 2 | 100.0 |
*Prenatal Diagnosis | 9 | 3.0 |
Syndrome | 2 | 0.0 |
Macaca mulatta | 3 | 0.0 |
Substantia Innominata/enzymology | 2 | 50.0 |
Caudate Nucleus/enzymology | 2 | 22.0 |
Isoelectric Focusing | 4 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Alzheimer Disease/enzymology | 4 | 26.0 |
Caudate Nucleus/*enzymology | 2 | 50.0 |
Receptors, Nicotinic/*physiology | 2 | 28.0 |
Xenopus laevis | 3 | 0.0 |
Circular Dichroism | 4 | 0.0 |
Neurofibrillary Tangles/*enzymology/pathology | 2 | 33.0 |
Tryptophan/chemistry | 2 | 5.0 |
Microinjections | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Fluorescent Antibody Technique | 8 | 0.0 |
Blood Platelets/enzymology | 2 | 4.0 |
*Enzyme Tests | 7 | 10.0 |
Lymphocytes/*enzymology | 3 | 4.0 |
Antibodies, Monoclonal | 7 | 0.0 |
Chlorpyrifos/*toxicity | 2 | 50.0 |
Isomerism | 3 | 1.0 |
Psychomotor Performance/*drug effects | 2 | 20.0 |
Fetus | 5 | 0.0 |
Acetylcholinesterase/immunology/*isolation & purification | 2 | 100.0 |
*Brain Chemistry | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel/methods | 2 | 1.0 |
Axons/enzymology | 2 | 28.0 |
Brain/*enzymology/pathology | 2 | 12.0 |
Chemistry, Physical | 2 | 1.0 |
Physostigmine/pharmacology | 4 | 25.0 |
Soman/pharmacology | 2 | 50.0 |
Muscles/drug effects/*enzymology | 2 | 50.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Amniotic Fluid/*chemistry | 3 | 6.0 |
Evaluation Studies | 2 | 0.0 |
Pregnancy Trimester, Third | 2 | 1.0 |
Abdominal Muscles/*abnormalities | 3 | 42.0 |
*Amniocentesis | 2 | 8.0 |
Precipitin Tests | 3 | 0.0 |
Brain/drug effects/*enzymology | 4 | 36.0 |
Cholinesterases/metabolism | 3 | 27.0 |
Electron Spin Resonance Spectroscopy | 2 | 0.0 |
Motor Endplate/enzymology | 3 | 100.0 |
Myocardium/*enzymology | 2 | 2.0 |
Corpus Striatum/*metabolism/pathology | 2 | 25.0 |
Membranes/enzymology | 2 | 22.0 |
Cell Separation | 3 | 0.0 |
Cholinesterase Inhibitors | 9 | 81.0 |
Dichlorvos/pharmacology | 2 | 100.0 |
*Mutagenesis, Site-Directed | 2 | 2.0 |
Acetylcholine/blood | 2 | 66.0 |
Substrate Specificity/drug effects | 2 | 15.0 |
Hamsters | 3 | 0.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Polyethylene Glycols | 6 | 7.0 |
Precipitation | 2 | 1.0 |
Neurotransmitters/*metabolism | 3 | 10.0 |
Alzheimer Disease/*pathology | 4 | 7.0 |
Basal Ganglia/*pathology | 2 | 33.0 |
Rats, Inbred Strains | 10 | 1.0 |
Cholinesterases/*genetics | 2 | 18.0 |
Acetylcholinesterase/blood/chemistry/*metabolism | 2 | 100.0 |
Immunologic Techniques | 4 | 1.0 |
*Cholinergic Fibers | 2 | 100.0 |
Amyloid beta-Protein/*metabolism | 3 | 3.0 |
Nerve Degeneration | 2 | 3.0 |
Cholinesterases/*blood | 6 | 33.0 |
Hemolysis | 3 | 0.0 |
Alzheimer Disease/cerebrospinal fluid/*enzymology | 2 | 100.0 |
Signal Transduction | 2 | 0.0 |
Acetylcholinesterase/*chemistry/isolation & purification | 2 | 100.0 |
Phosphoric Diester Hydrolases/*metabolism | 2 | 8.0 |
Fluorescence Polarization | 2 | 3.0 |
Serotonin/*metabolism | 2 | 4.0 |
Embryo | 3 | 0.0 |
Acetylcholinesterase | 2 | 66.0 |
Anencephaly/diagnosis | 2 | 18.0 |
Fetal Death/diagnosis | 3 | 37.0 |
Spectrophotometry | 3 | 1.0 |
*Fetal Death | 2 | 40.0 |
*Pregnancy, Multiple | 3 | 23.0 |
Ultrasonography | 3 | 3.0 |
Acetylcholinesterase/*analysis/metabolism | 2 | 100.0 |
Aging | 3 | 0.0 |
alpha-Fetoproteins/*analysis | 7 | 1.0 |
DNA/genetics | 4 | 0.0 |
Genes, Structural | 2 | 0.0 |
Diagnostic Errors | 2 | 2.0 |
Hippocampus/anatomy & histology/*enzymology | 2 | 100.0 |
Aging/*cerebrospinal fluid | 2 | 33.0 |
Acetylcholinesterase/*chemistry/genetics/*metabolism | 2 | 100.0 |
Horses | 2 | 1.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Organothiophosphorus Compounds/*pharmacology | 3 | 75.0 |
Organophosphorus Compounds/antagonists & inhibitors | 2 | 100.0 |
Cholinesterase Inhibitors/*chemistry | 2 | 100.0 |
Antibodies/immunology | 2 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Epitopes/immunology | 2 | 0.0 |
Immunosorbent Techniques | 3 | 1.0 |
Acetylcholinesterase/*metabolism/physiology | 2 | 100.0 |
Hemoglobins/biosynthesis | 2 | 12.0 |
Choline/*cerebrospinal fluid | 4 | 100.0 |
Alzheimer Disease/*diagnosis | 2 | 25.0 |
Neural Tube Defects/*diagnosis | 11 | 28.0 |
Brain/*pathology | 2 | 1.0 |
Hippocampus/pathology | 2 | 5.0 |
Isoenzymes/*metabolism | 5 | 1.0 |
Swine | 3 | 0.0 |
Cerebral Cortex/enzymology | 7 | 33.0 |
Spinal Cord/enzymology | 2 | 22.0 |
Hirschsprung Disease/*pathology | 3 | 30.0 |
Histological Techniques | 2 | 4.0 |
Catecholamines/*metabolism | 2 | 3.0 |
Tyrosine 3-Monooxygenase/metabolism | 2 | 1.0 |
Amniotic Fluid/*analysis | 4 | 5.0 |
Brain/enzymology/*metabolism | 2 | 14.0 |
Soman/*antagonists & inhibitors | 2 | 100.0 |
Aging/*physiology | 2 | 0.0 |
Antigen-Antibody Complex | 2 | 1.0 |
Antigens, CD55 | 3 | 1.0 |
*Genes, Structural | 2 | 0.0 |
Homovanillic Acid/cerebrospinal fluid | 2 | 13.0 |
Eels | 2 | 33.0 |
Antidotes/*pharmacology | 2 | 40.0 |
Muscles/*enzymology | 4 | 5.0 |
Acetylcholinesterase/*deficiency | 2 | 50.0 |
Autoantibodies | 2 | 6.0 |
Cerebellum/enzymology | 2 | 18.0 |
alpha-Fetoproteins/analysis | 3 | 1.0 |
Suicide | 2 | 40.0 |
False Negative Reactions | 2 | 1.0 |
Hippocampus/enzymology | 3 | 14.0 |
Macaca fascicularis | 4 | 1.0 |
Nerve Fibers/enzymology | 3 | 42.0 |
Fetal Diseases/*diagnosis | 2 | 5.0 |
Butyrylcholinesterase/cerebrospinal fluid | 2 | 66.0 |
Butyrylcholinesterase/analysis | 2 | 66.0 |
Methods | 2 | 0.0 |
Amyotrophic Lateral Sclerosis/enzymology | 3 | 50.0 |
Dementia/enzymology | 3 | 50.0 |
Parkinson Disease/enzymology | 3 | 37.0 |
Cerebrospinal Fluid Proteins/metabolism | 2 | 50.0 |
Neurofibrils/*pathology | 2 | 25.0 |
Aging/physiology | 2 | 1.0 |
Hirschsprung Disease/diagnosis | 2 | 100.0 |
gamma-Glutamyltransferase/*metabolism | 2 | 33.0 |
Cerebrospinal Fluid Proteins/analysis | 2 | 8.0 |
Dementia/*cerebrospinal fluid | 2 | 18.0 |
Cholinergic Fibers/pathology | 2 | 66.0 |
Cell Membrane Permeability | 2 | 1.0 |
Amyloid beta-Protein/*cerebrospinal fluid | 2 | 12.0 |
tau Proteins/*cerebrospinal fluid | 2 | 20.0 |
Chemistry | 2 | 0.0 |
Drug Stability | 2 | 0.0 |
Neuromuscular Junction/enzymology | 3 | 75.0 |
Parathion/poisoning | 2 | 100.0 |
Cytoplasm/enzymology | 3 | 3.0 |
Rectum/*enzymology | 4 | 80.0 |
Alzheimer Disease/*cerebrospinal fluid | 3 | 16.0 |
Blood Platelets/*enzymology | 2 | 2.0 |
Mice, Neurologic Mutants | 2 | 1.0 |
Antibody Affinity | 3 | 1.0 |
Sodium Chloride/pharmacology | 2 | 2.0 |
Glutamate Decarboxylase/metabolism | 2 | 11.0 |
Intestinal Mucosa/*enzymology/pathology | 2 | 33.0 |
Acetylcholinesterase/*isolation & purification | 2 | 100.0 |
Butyrylcholinesterase/chemistry | 4 | 66.0 |
Rectum/enzymology | 2 | 66.0 |
Rectum/enzymology/innervation | 2 | 100.0 |
Intestinal Mucosa/enzymology | 2 | 6.0 |
Autopsy | 2 | 1.0 |
Ca(2+) Mg(2+)-ATPase | 2 | 28.0 |
Na(+)-K(+)-Exchanging ATPase/metabolism | 2 | 4.0 |
Dementia/*enzymology | 2 | 20.0 |
Creatine Kinase/blood | 2 | 1.0 |
Auditory Cortex/*embryology/enzymology | 2 | 100.0 |
Risk | 2 | 0.0 |
Na(+)-K(+)-Exchanging ATPase/*blood | 2 | 10.0 |
Intestinal Mucosa/*enzymology | 2 | 10.0 |
Occupational Diseases/*chemically induced | 2 | 20.0 |
Organophosphorus Compounds/urine | 2 | 100.0 |
Acetylthiocholine | 2 | 100.0 |
Megacolon/*diagnosis/enzymology | 2 | 100.0 |
*Ultraviolet Rays | 2 | 0.0 |
Antioxidants/pharmacology | 2 | 1.0 |
Genes, Reporter | 2 | 0.0 |
Cell Adhesion | 2 | 0.0 |
Cholinesterase Inhibitors/*chemical synthesis/chemistry/*therapeutic use | 2 | 100.0 |
